Madrigal Pharmaceuticals Files 8-K on Financials
Ticker: MDGL · Form: 8-K · Filed: Aug 7, 2024 · CIK: 1157601
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
Madrigal Pharma dropped an 8-K detailing their financials. Check it out.
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on August 7, 2024, reporting on its results of operations and financial condition. The filing details financial statements and exhibits related to the company's performance. Madrigal Pharmaceuticals, Inc. is incorporated in Delaware and is headquartered in West Conshohocken, Pennsylvania.
Why It Matters
This 8-K filing provides investors with crucial updates on Madrigal Pharmaceuticals' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- August 7, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- West Conshohocken, Pennsylvania (location) — Address of principal executive offices
- SYNTA PHARMACEUTICALS CORP (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Madrigal Pharmaceuticals, Inc.'s Results of Operations and Financial Condition, along with Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 7, 2024.
In which state is Madrigal Pharmaceuticals, Inc. incorporated?
Madrigal Pharmaceuticals, Inc. is incorporated in Delaware.
What is the business address of Madrigal Pharmaceuticals, Inc.?
The business address of Madrigal Pharmaceuticals, Inc. is Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428.
What was Madrigal Pharmaceuticals, Inc.'s former company name?
Madrigal Pharmaceuticals, Inc.'s former company name was SYNTA PHARMACEUTICALS CORP.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-08-07 07:06:32
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share MDGL The Nasdaq
Filing Documents
- d813823d8k.htm (8-K) — 24KB
- d813823dex991.htm (EX-99.1) — 66KB
- g813823g30j89.jpg (GRAPHIC) — 4KB
- 0001193125-24-195400.txt ( ) — 229KB
- mdgl-20240807.xsd (EX-101.SCH) — 3KB
- mdgl-20240807_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240807_pre.xml (EX-101.PRE) — 11KB
- d813823d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release of Madrigal Pharmaceuticals, Inc., dated August 7, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Mardi C. Dier Name: Mardi C. Dier Title: Senior Vice President and Chief Financial Officer Date: August 7, 2024